JP2017532360A5 - - Google Patents

Download PDF

Info

Publication number: JP2017532360A5
Authority: JP; Japan
Prior art keywords: methyl; oxo; dimethyl; carboxamide; propyl
Prior art date: 2015-10-28
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

JP2017522890A

Other languages

English (en)

Japanese (ja)

Other versions

JP6571180B2 (ja

JP2017532360A (ja

Filing date

2015-10-28

Publication date

2018-12-06

2015-10-28 Application filed filed Critical

2015-10-28 Priority claimed from PCT/EP2015/075009 external-priority patent/WO2016066697A1/en

2017-11-02 Publication of JP2017532360A publication Critical patent/JP2017532360A/ja

2018-12-06 Publication of JP2017532360A5 publication Critical patent/JP2017532360A5/ja

2019-09-04 Application granted granted Critical

2019-09-04 Publication of JP6571180B2 publication Critical patent/JP6571180B2/ja

Status Expired - Fee Related legal-status Critical Current

2035-10-28 Anticipated expiration legal-status Critical

Links

150000001875 compounds Chemical class 0.000 claims 16
150000003839 salts Chemical class 0.000 claims 15
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 4
239000008194 pharmaceutical composition Substances 0.000 claims 4
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
208000008839 Kidney Neoplasms Diseases 0.000 claims 2
206010028980 Neoplasm Diseases 0.000 claims 2
206010038389 Renal cancer Diseases 0.000 claims 2
201000011510 cancer Diseases 0.000 claims 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
229910052739 hydrogen Inorganic materials 0.000 claims 2
239000001257 hydrogen Substances 0.000 claims 2
201000010982 kidney cancer Diseases 0.000 claims 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
-1 oxazolylmethyl Chemical group 0.000 claims 2
125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
ZGINJZVAJWSMEY-UHFFFAOYSA-N 2-[1-[1-(2,2-difluoropropyl)piperidin-4-yl]propyl]-5-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-3-methyl-6,7-dihydrothieno[3,2-c]pyridin-4-one Chemical compound CCC(C1CCN(CC(C)(F)F)CC1)C1=C(C)C2=C(CCN(CC3=C(C)C=C(C)NC3=O)C2=O)S1 ZGINJZVAJWSMEY-UHFFFAOYSA-N 0.000 claims 1
ABYOCYPONVIIAR-UHFFFAOYSA-N 2-[1-[4-(dimethylamino)piperidin-1-yl]propyl]-5-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-3-methyl-6,7-dihydrothieno[3,2-c]pyridin-4-one Chemical compound CC1=C(C(NC(=C1)C)=O)CN1C(C2=C(CC1)SC(=C2C)C(CC)N1CCC(CC1)N(C)C)=O ABYOCYPONVIIAR-UHFFFAOYSA-N 0.000 claims 1
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
GTNKQQKZLOXKKJ-OAHLLOKOSA-N 5-[(1R)-1-[1-(2,2-difluoroethyl)piperidin-4-yl]ethyl]-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-4-methylthiophene-3-carboxamide Chemical compound C[C@H](C1CCN(CC(F)F)CC1)C1=C(C)C(=CS1)C(=O)NCC1=C(C)C=C(C)NC1=O GTNKQQKZLOXKKJ-OAHLLOKOSA-N 0.000 claims 1
ICLKDBHKJKQWFI-GOSISDBHSA-N 5-[(1R)-1-[1-(2,2-difluoroethyl)piperidin-4-yl]propyl]-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-4-methylthiophene-3-carboxamide Chemical compound CC[C@H](C1CCN(CC(F)F)CC1)C1=C(C)C(=CS1)C(=O)NCC1=C(C)C=C(C)NC1=O ICLKDBHKJKQWFI-GOSISDBHSA-N 0.000 claims 1
ZTKJBAWUDZMEOX-LJQANCHMSA-N 5-[(1R)-1-[1-(2,2-difluoropropyl)piperidin-4-yl]propyl]-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-4-methylthiophene-3-carboxamide Chemical compound FC(CN1CCC(CC1)[C@@H](CC)C1=C(C(=CS1)C(=O)NCC=1C(NC(=CC=1C)C)=O)C)(C)F ZTKJBAWUDZMEOX-LJQANCHMSA-N 0.000 claims 1
ZTKJBAWUDZMEOX-IBGZPJMESA-N 5-[(1S)-1-[1-(2,2-difluoropropyl)piperidin-4-yl]propyl]-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-4-methylthiophene-3-carboxamide Chemical compound CC[C@@H](C1CCN(CC(C)(F)F)CC1)C1=C(C)C(=CS1)C(=O)NCC1=C(C)C=C(C)NC1=O ZTKJBAWUDZMEOX-IBGZPJMESA-N 0.000 claims 1
QYQMXWRRXKMXGX-UHFFFAOYSA-N 5-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-2-[1-[1-(2-fluoropropyl)piperidin-4-yl]propyl]-3-methyl-6,7-dihydrothieno[3,2-c]pyridin-4-one Chemical compound CC1=C(C(NC(=C1)C)=O)CN1C(C2=C(CC1)SC(=C2C)C(CC)C1CCN(CC1)CC(C)F)=O QYQMXWRRXKMXGX-UHFFFAOYSA-N 0.000 claims 1
ICLKDBHKJKQWFI-UHFFFAOYSA-N 5-[1-[1-(2,2-difluoroethyl)piperidin-4-yl]propyl]-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-4-methylthiophene-3-carboxamide Chemical compound CCC(C1CCN(CC(F)F)CC1)C1=C(C)C(=CS1)C(=O)NCC1=C(C)C=C(C)NC1=O ICLKDBHKJKQWFI-UHFFFAOYSA-N 0.000 claims 1
SHUSPCBTMDNIOC-UHFFFAOYSA-N 5-[1-[1-(2,2-difluoroethyl)piperidin-4-ylidene]propyl]-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-4-methylthiophene-3-carboxamide Chemical compound CCC(C1=C(C)C(=CS1)C(=O)NCC1=C(C)C=C(C)NC1=O)=C1CCN(CC(F)F)CC1 SHUSPCBTMDNIOC-UHFFFAOYSA-N 0.000 claims 1
JDCNHCLKYOTREH-UHFFFAOYSA-N 5-[1-[1-(2,2-difluoropropyl)piperidin-4-ylidene]propyl]-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-4-methylthiophene-3-carboxamide Chemical compound FC(CN1CCC(CC1)=C(CC)C1=C(C(=CS1)C(=O)NCC=1C(NC(=CC=1C)C)=O)C)(C)F JDCNHCLKYOTREH-UHFFFAOYSA-N 0.000 claims 1
FWCNVCGKQUQSRK-UHFFFAOYSA-N 5-[1-[1-(N-cyano-N'-methylcarbamimidoyl)piperidin-4-yl]propyl]-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-4-methylthiophene-3-carboxamide Chemical compound C(#N)N=C(NC)N1CCC(CC1)C(CC)C1=C(C(=CS1)C(=O)NCC=1C(NC(=CC=1C)C)=O)C FWCNVCGKQUQSRK-UHFFFAOYSA-N 0.000 claims 1
QWNARTFIXGUQQK-UHFFFAOYSA-N 5-[1-[1-(N-cyano-N'-methylcarbamimidoyl)piperidin-4-ylidene]propyl]-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-4-methylthiophene-3-carboxamide Chemical compound C(#N)N=C(NC)N1CCC(CC1)=C(CC)C1=C(C(=CS1)C(=O)NCC=1C(NC(=CC=1C)C)=O)C QWNARTFIXGUQQK-UHFFFAOYSA-N 0.000 claims 1
CASPUOMRDFIWFM-UHFFFAOYSA-N 5-[1-[1-(dimethylamino)piperidin-4-ylidene]propyl]-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-4-methylthiophene-3-carboxamide Chemical compound CCC(C1=C(C)C(=CS1)C(=O)NCC1=C(C)C=C(C)NC1=O)=C1CCN(CC1)N(C)C CASPUOMRDFIWFM-UHFFFAOYSA-N 0.000 claims 1
IDUHGUNBWPHVAI-UHFFFAOYSA-N 5-[1-[4-(dimethylamino)cyclohexyl]propyl]-n-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methyl]-4-methylthiophene-3-carboxamide Chemical compound S1C=C(C(=O)NCC=2C(NC(C)=CC=2C)=O)C(C)=C1C(CC)C1CCC(N(C)C)CC1 IDUHGUNBWPHVAI-UHFFFAOYSA-N 0.000 claims 1
OCVFHWCDYDBBRP-UHFFFAOYSA-N 5-[1-[4-(dimethylamino)piperidin-1-yl]ethyl]-n-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methyl]-4-methylthiophene-3-carboxamide Chemical compound S1C=C(C(=O)NCC=2C(NC(C)=CC=2C)=O)C(C)=C1C(C)N1CCC(N(C)C)CC1 OCVFHWCDYDBBRP-UHFFFAOYSA-N 0.000 claims 1
LVGCTQDARMZPSW-UHFFFAOYSA-N 5-[1-[4-(dimethylamino)piperidin-1-yl]propyl]-n-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methyl]-4-methylthiophene-3-carboxamide Chemical compound S1C=C(C(=O)NCC=2C(NC(C)=CC=2C)=O)C(C)=C1C(CC)N1CCC(N(C)C)CC1 LVGCTQDARMZPSW-UHFFFAOYSA-N 0.000 claims 1
XHROKJJCFRMCBT-UHFFFAOYSA-N 5-[[4-(dimethylamino)cyclohexyl]-ethylamino]-n-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methyl]-4-methylthiophene-3-carboxamide Chemical compound S1C=C(C(=O)NCC=2C(NC(C)=CC=2C)=O)C(C)=C1N(CC)C1CCC(N(C)C)CC1 XHROKJJCFRMCBT-UHFFFAOYSA-N 0.000 claims 1
206010005003 Bladder cancer Diseases 0.000 claims 1
206010005949 Bone cancer Diseases 0.000 claims 1
208000018084 Bone neoplasm Diseases 0.000 claims 1
208000003174 Brain Neoplasms Diseases 0.000 claims 1
206010006187 Breast cancer Diseases 0.000 claims 1
208000026310 Breast neoplasm Diseases 0.000 claims 1
KWPFVIZLZMVNJS-UHFFFAOYSA-N CC(C1CCN(CC(C)(F)F)CC1)C1=C(C(NCC2=C(C)C=C(C)NC2=O)=O)C(C)=CS1 Chemical compound CC(C1CCN(CC(C)(F)F)CC1)C1=C(C(NCC2=C(C)C=C(C)NC2=O)=O)C(C)=CS1 KWPFVIZLZMVNJS-UHFFFAOYSA-N 0.000 claims 1
206010009944 Colon cancer Diseases 0.000 claims 1
208000012609 Cowden disease Diseases 0.000 claims 1
201000002847 Cowden syndrome Diseases 0.000 claims 1
206010014967 Ependymoma Diseases 0.000 claims 1
208000006168 Ewing Sarcoma Diseases 0.000 claims 1
208000007569 Giant Cell Tumors Diseases 0.000 claims 1
208000032612 Glial tumor Diseases 0.000 claims 1
206010018338 Glioma Diseases 0.000 claims 1
102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 claims 1
101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 claims 1
208000005726 Inflammatory Breast Neoplasms Diseases 0.000 claims 1
206010021980 Inflammatory carcinoma of the breast Diseases 0.000 claims 1
206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
206010025323 Lymphomas Diseases 0.000 claims 1
208000000172 Medulloblastoma Diseases 0.000 claims 1
208000008770 Multiple Hamartoma Syndrome Diseases 0.000 claims 1
241001529936 Murinae Species 0.000 claims 1
LOYKAXLOUFUJMQ-UHFFFAOYSA-N N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-5-[1-(1-hydroxypiperidin-4-ylidene)propyl]-4-methylthiophene-3-carboxamide Chemical compound CCC(C1=C(C)C(=CS1)C(=O)NCC1=C(C)C=C(C)NC1=O)=C1CCN(O)CC1 LOYKAXLOUFUJMQ-UHFFFAOYSA-N 0.000 claims 1
IUHDGIJHSJSHEB-UHFFFAOYSA-N N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-5-[1-(4-hydroxycyclohexylidene)propyl]-4-methylthiophene-3-carboxamide Chemical compound CC1=C(C(NC(=C1)C)=O)CNC(=O)C1=CSC(=C1C)C(CC)=C1CCC(CC1)O IUHDGIJHSJSHEB-UHFFFAOYSA-N 0.000 claims 1
VCELFVLWXRMZGZ-UHFFFAOYSA-N N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-5-[1-[1-(2-fluoro-2-methylpropyl)piperidin-4-yl]propyl]-4-methylthiophene-3-carboxamide Chemical compound CCC(C1CCN(CC(C)(C)F)CC1)C1=C(C)C(=CS1)C(=O)NCC1=C(C)C=C(C)NC1=O VCELFVLWXRMZGZ-UHFFFAOYSA-N 0.000 claims 1
206010033128 Ovarian cancer Diseases 0.000 claims 1
206010061535 Ovarian neoplasm Diseases 0.000 claims 1
206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
206010060862 Prostate cancer Diseases 0.000 claims 1
208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
206010039491 Sarcoma Diseases 0.000 claims 1
208000005718 Stomach Neoplasms Diseases 0.000 claims 1
208000024770 Thyroid neoplasm Diseases 0.000 claims 1
208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
208000008383 Wilms tumor Diseases 0.000 claims 1
210000000988 bone and bone Anatomy 0.000 claims 1
210000004556 brain Anatomy 0.000 claims 1
208000029742 colonic neoplasm Diseases 0.000 claims 1
201000010099 disease Diseases 0.000 claims 1
208000035475 disorder Diseases 0.000 claims 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
206010017758 gastric cancer Diseases 0.000 claims 1
208000005017 glioblastoma Diseases 0.000 claims 1
201000010536 head and neck cancer Diseases 0.000 claims 1
208000014829 head and neck neoplasm Diseases 0.000 claims 1
125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
201000004653 inflammatory breast carcinoma Diseases 0.000 claims 1
208000032839 leukemia Diseases 0.000 claims 1
201000007270 liver cancer Diseases 0.000 claims 1
208000014018 liver neoplasm Diseases 0.000 claims 1
201000005202 lung cancer Diseases 0.000 claims 1
208000020816 lung neoplasm Diseases 0.000 claims 1
208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
230000001404 mediated effect Effects 0.000 claims 1
201000001441 melanoma Diseases 0.000 claims 1
239000000203 mixture Substances 0.000 claims 1
FBXFKRLTSXFVRZ-UHFFFAOYSA-N n-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methyl]-5-[ethyl-[4-[ethyl(methyl)amino]cyclohexyl]amino]-4-methylthiophene-3-carboxamide Chemical compound C1CC(N(C)CC)CCC1N(CC)C1=C(C)C(C(=O)NCC=2C(NC(C)=CC=2C)=O)=CS1 FBXFKRLTSXFVRZ-UHFFFAOYSA-N 0.000 claims 1
201000008026 nephroblastoma Diseases 0.000 claims 1
201000008968 osteosarcoma Diseases 0.000 claims 1
201000002528 pancreatic cancer Diseases 0.000 claims 1
208000008443 pancreatic carcinoma Diseases 0.000 claims 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
125000000714 pyrimidinyl group Chemical group 0.000 claims 1
201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
201000011549 stomach cancer Diseases 0.000 claims 1
208000011580 syndromic disease Diseases 0.000 claims 1
DAUYIKBTMNZABP-UHFFFAOYSA-N thiophene-3-carboxamide Chemical compound NC(=O)C=1C=CSC=1 DAUYIKBTMNZABP-UHFFFAOYSA-N 0.000 claims 1
201000002510 thyroid cancer Diseases 0.000 claims 1
201000005112 urinary bladder cancer Diseases 0.000 claims 1
0 **(CC1)CC*1=*(*)c1c(*)c(C(N(*)CC2=C(*)C=C(*)NC2=O)=O)c(*)[s]1 Chemical compound **(CC1)CC*1=*(*)c1c(*)c(C(N(*)CC2=C(*)C=C(*)NC2=O)=O)c(*)[s]1 0.000 description 1

JP2017522890A 2014-10-28 2015-10-28 Ｚｅｓｔｅホモログ２エンハンサー阻害剤 Expired - Fee Related JP6571180B2 (ja)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US201462069438P	2014-10-28	2014-10-28
US62/069,438		2014-10-28
US201462075596P	2014-11-05	2014-11-05
US62/075,596		2014-11-05
PCT/EP2015/075009 WO2016066697A1 (en)	2014-10-28	2015-10-28	Enhancer of zeste homolog 2 inhibitors

Publications (3)

Publication Number	Publication Date
JP2017532360A JP2017532360A (ja)	2017-11-02
JP2017532360A5 true JP2017532360A5 (2)	2018-12-06
JP6571180B2 JP6571180B2 (ja)	2019-09-04

Family

ID=54360465

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2017522890A Expired - Fee Related JP6571180B2 (ja)	2014-10-28	2015-10-28	Ｚｅｓｔｅホモログ２エンハンサー阻害剤

Country Status (11)

Country	Link
US (1)	US20170334891A1 (2)
EP (1)	EP3212639A1 (2)
JP (1)	JP6571180B2 (2)
KR (1)	KR20170068603A (2)
CN (1)	CN107148419A (2)
AU (1)	AU2015340614B2 (2)
BR (1)	BR112017008840A2 (2)
CA (1)	CA2965729A1 (2)
MA (1)	MA40848A (2)
RU (1)	RU2017118165A (2)
WO (1)	WO2016066697A1 (2)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UY36758A (es) *	2015-06-30	2016-12-30	Glaxosmithkline Ip No 2 Ltd	Inhibidores del potenciador del homólogo zeste 2
TW201718598A (zh)	2015-08-27	2017-06-01	美國禮來大藥廠	Ｅｚｈ２抑制劑
CA3023157A1 (en) *	2016-05-05	2017-11-09	Glaxosmithkline Intellectual Property (No.2) Limited	Enhancer of zeste homolog 2 inhibitors
JP7125353B2 (ja)	2017-01-19	2022-08-24	第一三共株式会社	Ｈｔｌｖ－１関連脊髄症を治療することに用いるための医薬組成物
US10266542B2 (en)	2017-03-15	2019-04-23	Mirati Therapeutics, Inc.	EZH2 inhibitors
WO2018177993A1 (de)	2017-03-31	2018-10-04	Bayer Cropscience Aktiengesellschaft	Pyrazole zur bekämpfung von arthropoden
DK3746446T3 (da)	2018-01-31	2022-06-27	Mirati Therapeutics Inc	PRC2-inhibitorer
CN120097995A (zh)	2018-05-21	2025-06-06	星座制药公司	甲基修饰酶的调节剂、其组合物和用途
CA3104209A1 (en)	2018-07-09	2020-01-16	Fondation Asile Des Aveugles	Inhibition of prc2 subunits to treat eye disorders
US12421228B2 (en)	2019-04-22	2025-09-23	Mirati Therapeutics, Inc.	Naphthyridine derivatives as PRC2 inhibitors
US12252493B2 (en)	2019-06-05	2025-03-18	Mirati Therapeutics, Inc.	Imidazo[1,2-c]pyrimidine derivatives as PRC2 inhibitors for treating cancer
WO2021016409A1 (en) *	2019-07-24	2021-01-28	Constellation Pharmaceuticals, Inc.	Ezh2 inhibition in combination therapies for the treatment of cancers
WO2021016414A1 (en)	2019-07-24	2021-01-28	Constellation Pharmaceuticals, Inc.	Crystalline forms of 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-n-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide
JP2022545467A (ja)	2019-08-22	2022-10-27	ジュノーセラピューティクスインコーポレイテッド	Ｔ細胞療法とｚｅｓｔｅホモログ２エンハンサー（ＥＺＨ２）阻害剤との併用療法および関連方法
CN110950834A (zh) *	2019-11-26	2020-04-03	济南大学	新型eed-ezh2相互作用小分子抑制剂的确定和评价
TW202400140A (zh)	2022-04-27	2024-01-01	日商第一三共股份有限公司	抗體-藥物結合物與ezh1及/或ezh2抑制劑之組合

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA110112C2 (uk) *	2010-05-07	2015-11-25	Глаксосмітклайн Ллс	Індоли
TWI598336B (zh) *	2011-04-13	2017-09-11	雅酶股份有限公司	經取代之苯化合物
JO3363B1 (ar) *	2011-04-13	2019-03-13	Epizyme Inc	مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
BR112014010803A2 (pt) *	2011-11-04	2017-04-25	Glaxosmithkline Intellectual Property (No 2) Ltd	método de tratamento
NZ628762A (en) *	2012-02-10	2016-07-29	Constellation Pharmaceuticals Inc	Modulators of methyl modifying enzymes, compositions and uses thereof
UA111305C2 (uk) *	2012-12-21	2016-04-11	Пфайзер Інк.	Конденсовані лактами арилу та гетероарилу
EP2991980B1 (en) *	2013-04-30	2019-01-02	Glaxosmithkline Intellectual Property (No. 2) Limited	Enhancer of zeste homolog 2 inhibitors
KR20160030221A (ko) *	2013-07-10	2016-03-16	글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드	제스트 인핸서 상동체 2 억제제

2015
- 2015-10-28 CN CN201580058856.7A patent/CN107148419A/zh active Pending
- 2015-10-28 KR KR1020177014034A patent/KR20170068603A/ko not_active Withdrawn
- 2015-10-28 RU RU2017118165A patent/RU2017118165A/ru not_active Application Discontinuation
- 2015-10-28 AU AU2015340614A patent/AU2015340614B2/en not_active Ceased
- 2015-10-28 JP JP2017522890A patent/JP6571180B2/ja not_active Expired - Fee Related
- 2015-10-28 MA MA040848A patent/MA40848A/fr unknown
- 2015-10-28 BR BR112017008840A patent/BR112017008840A2/pt not_active Application Discontinuation
- 2015-10-28 CA CA2965729A patent/CA2965729A1/en not_active Abandoned
- 2015-10-28 US US15/522,373 patent/US20170334891A1/en not_active Abandoned
- 2015-10-28 EP EP15786958.7A patent/EP3212639A1/en not_active Withdrawn
- 2015-10-28 WO PCT/EP2015/075009 patent/WO2016066697A1/en not_active Ceased

Publication	Publication Date	Title
JP2017532360A5 (2)	2018-12-06
RU2017118165A (ru)	2018-11-29	Ингибиторы энхансера гомолога 2 zestes
JP6873145B2 (ja)	2021-05-19	５−置換２−（モルホリン−４−イル）−１，７−ナフチリジン
AU2010286569B2 (en)	2013-10-10	Compounds and compositions as protein kinase inhibitors
JP2021138718A (ja)	2021-09-16	統合ストレス経路のモジュレーター
JP2016522246A5 (2)	2017-08-03
JP2016517878A5 (2)	2017-06-01
FI4161935T3 (fi)	2025-08-19	Brm:ään kohdennettuja yhdisteitä ja niihin liittyviä käyttömenetelmiä
CN114430740A (zh)	2022-05-03	Egfr抑制剂、组合物及其制备方法
JP2015529235A5 (2)	2018-02-08
SI2797918T1 (en)	2018-05-31	Bromodomain inhibitors
JP2008535903A5 (2)	2009-04-30
JP2016527263A5 (2)	2017-09-07
JP2019504009A5 (2)	2020-02-06
RU2015143717A (ru)	2017-04-28	2-Аминопиримидин-6-оны и аналоги, проявляющие противораковые и антипролиферативные действия
JP2016513660A5 (2)	2017-03-30
JP2014521653A5 (2)	2015-08-20
WO2015015318A4 (en)	2015-09-03	Novel quinazolinones as bromodomain inhibitors
JP2019517596A5 (2)	2020-07-27
WO2014145023A1 (en)	2014-09-18	1,2,4-triazol-5-ones and analogs exhibiting anti-cancer and anti-proliferative activities
JP2008528467A5 (2)	2009-03-19
IL291590B2 (en)	2023-11-01	Novel substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof
JP2012507566A5 (2)	2012-12-20
RU2009125897A (ru)	2011-01-20	Ингибиторы фосфоинозитид-3-киназы и способы их применения
WO2012000304A1 (zh)	2012-01-05	杂环炔苯类化合物及其药用组合物和应用